XDC Academy

Degrader-Antibody Conjugates (DACs), a revolutionary bioconjugate therapeutic class, lead the forefront of cancer treatment by using antibodies’ targeting precision to deliver protein degraders directly to cancer cells. Combining antibodies’ specificity with degraders’ protein-degrading potency, they offer a promising approach to overcome conventional antibody-drug conjugates (ADCs) limitations and redefine oncology precision and efficacy. While in early clinical exploration (most advanced in Phase I) with an expanding pipeline compared to mature ADCs, DACs have a transformative edge: addressing traditional ADCs’ insufficient antigen internalization and small-molecule degraders’ suboptimal pharmacokinetics. This unique value positions DACs as a frontier direction in next-generation antibody-conjugated therapeutics.

This slide deck comprehensively covers DACs, including their mechanism of action, key advantages, competitive landscape, and WuXi XDC’s leading DAC development capabilities and diverse bioconjugate services. It explores how WuXi XDC drives innovation via proprietary conjugation technologies and end-to-end services to accelerate progress in this transformative therapeutic field.